MPM has collected three China drugs for its ‘best of both worlds’ strategy
MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed three drug programs ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CN
- [HEALTH] Who writes the pandemic? State power, individual subjectivity, and the history of the present in China's COVID-19 respon
- [CONFLICT] Chinese-owned AESC sells controlling stake in US battery factory
- [CONFLICT] Africa: China's Zero-Tariff for African Products Takes Effect May 1 - Envoy
- [TECH] US stops exports of tools to China’s number two chip maker — Hua Hong and Huali Microelectronics reportedly on the cusp of starting a 7-nm fab in Shanghai
- [FINANCE] Mercedes-Benz Q1 2026 earnings: profit drops as China sales fall
- [AVIATION] China’s CIC considers selling Heathrow stake over third runway cost worries